RLS Therapeutics is a cutting-edge brand specializing in the development of a breakthrough small molecule therapeutic. Their proprietary class of compounds is designed to address a wide range of disease indications, offering hope to patients worldwide. Their innovative technology, known as RPRx (Recycling Polycarbonyl Redox Therapy), targets health disorders resulting from disabled mitochondrial function.

What sets RLS Therapeutics apart is their emphasis on decreasing the risk in drug development while focusing on disease indications that have a profoundly positive impact on human health. With an experienced team of founders and advisory board members, their molecule class has demonstrated strong efficacy in treating various health issues during initial studies. Additionally, the broad range of potential indications they explore increases the likelihood of developmental success.

Headquartered in Nashville, TN, RLS Therapeutics welcomes inquiries from individuals who are interested in their groundbreaking work. They are dedicated to driving forward advancements in therapeutic development and improving the well-being of patients worldwide